tbuckley/cabot-search huggingface dataset:
Update in Women's Health
Authors: Roy Verdery
Journal: Annals of Internal Medicine (2000)

Letters5 September 2000Update in Women's HealthRoy Verdery, PhD, MDRoy Verdery, PhD, MDUniversity of Arkansas for Medical Sciences; Little Rock, AR 72205 (Verdery)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-5-200009050-00017 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:One of the comments in the Update in Women's Health (1) on the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) (2) is an astute pickup by the authors. Lovastatin apparently “saved” only six women from a “primary end point”—myocardial infarction, sudden death, or unstable angina—but appeared to be associated with four additional cases of breast cancer. In a much more damning article by the Cholesterol and Recurrent Events (CARE) investigators (3), which was also cited in the Update, 12 cases of breast cancer occurred in patients receiving pravastatin, but only 1 case occurred among those receiving placebo ...References1. Charney P, Walsh J, Nattinger AB. Update in women's health. Ann Intern Med. 1999;131:952-8. LinkGoogle Scholar2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al . Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22. CrossrefMedlineGoogle Scholar3. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial Investigators. N Engl J Med. 1996;335:1001-9. CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Arkansas for Medical Sciences; Little Rock, AR 72205 (Verdery) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoUpdate in Women's Health Pamela Charney , Judith Walsh , and Ann B. Nattinger Update in Women's Health Pamela Charney and Judith Walsh Metrics 5 September 2000Volume 133, Issue 5Page: 391KeywordsBreast cancerCholesterolCoronary arteriesDrugsInfarctionObstetrics and gynecologyStable coronary artery diseaseStatins ePublished: 5 September 2000 Issue Published: 5 September 2000 CopyrightCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Points from Letters: Hazards of Argyll Trocar Catheter
Authors: J. Bradley
Journal: BMJ (1975)

Ketoprofen, one of the many propionic acid derivatives flooding the market, is the subject of another substantial promotional programme only 12 months after the first. . ..Pharmaceutical companies, it seems, are playing into the hands of "Bennery" witlh such blatant "burning" of profits.. The public can hardly be expected to support the call for more money for the N.H.S. when it seems the medical profession is doing little to discourage such wasteful practices....
UK report warns of continued increase in HIV infection
Authors: Susan Mayor
Journal: BMJ (2004)

The number of people infected with HIV is continuing to increase in the United Kingdom, warned a report published this week.

“The figures at the end of 2003 remain startling,” noted the report, Focus on Prevention , which was the second annual surveillance report from the Health Protection Agency. Surveillance data showed an estimated 53 000 people had HIV in the United Kingdom at the end of 2003. Just over a quarter (27%) of these were unaware of their infection.

The number of new HIV diagnoses in 2003 was 6606—more than double …
Time's Up
Authors: Stephen Raffanti
Journal: Annals of Internal Medicine (2006)

On Being a Doctor4 July 2006Time's UpStephen Raffanti, MD, MPHStephen Raffanti, MD, MPHFrom Vanderbilt University, Nashville, TN 37203.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-145-1-200607040-00013 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Maggie sat staring in the exam room, remnants of the hot Tennessee sun darkening her white blouse. I had originally misinterpreted her blank stare as a sign of indifference. But now, after years of office visits, hospitalizations, and family strife and care, I realized that her stare was part of her way of dealing with a less-than-generous lot in life. Maggie had indirectly benefited from her diagnosis of HIV infection. She had never before received care in a comprehensive health system, but her diagnosis of HIV and resultant TennCare coverage allowed her to be seen regularly by a medical provider ... Author, Article, and Disclosure InformationAffiliations: From Vanderbilt University, Nashville, TN 37203.Corresponding Author: Stephen Raffanti, MD, MPH, Comprehensive Care Center, 345 24th Avenue North, Suite 103, Nashville, TN 37203; e-mail, [email protected]org. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 4 July 2006Volume 145, Issue 1Page: 73-74KeywordsHIVHIV infectionsHeartQuality of lifeRunningSafetySleepStomachTongueViremia ePublished: 4 July 2006 Issue Published: 4 July 2006 Copyright & PermissionsCopyright © 2006 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Bone marrow progenitor cell reserve and function and stromal cell function are defective in rheumatoid arthritis: evidence for a tumor necrosis factor alpha–mediated effect
Authors: Helen A. Papadaki, Heraklis D. Kritikos, Claudia Gemetzi, Helen Koutala, Judith C. W. Marsh, Dimitrios T. Boumpas, George D. Eliopoulos
Journal: Blood (2002)
The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)–like disease
Authors: Yoshiyuki Yamada, Marc E. Rothenberg, Andrew W. Lee, Hiroko Saito Akei, Eric B. Brandt, David A. Williams, Jose A. Cancelas
Journal: Blood (2006)
Electrical Coupling Mediates Tunable Low-Frequency Oscillations and Resonance in the Cerebellar Golgi Cell Network
Authors: Guillaume P. Dugué, Nicolas Brunel, Vincent Hakim, Eric Schwartz, Mireille Chat, Maxime Lévesque, Richard Courtemanche, Clément Léna, Stéphane Dieudonné
Journal: Neuron (2009)
Correlation of the clinical manifestations and gene mutations of Japanese xeroderma pigmentosum group A patients
Authors: M. KONDOHI, M. UEDA, M. ICHIHASHI
Journal: British Journal of Dermatology (1995)

The gene responsible for xeroderma pigmentosum (XP) group A has recently been cloned and designated XPA gene. Previous studies have shown that most Japanese XPA patients have homozygous mutations for the splicing site of intron 3 of the XPA gene, which was recognized by restriction endonuclease (RE) AlwNI (AlwNI mutation). Other mutations found to date have been the nonsense mutation at codon 228 in exon 6, recognized by RE Hphi (HphI mutation), and at codon 116 in exon 3, recognized by RE Msel (Msel mutation). Using polymerase chain reaction restriction fragment length polymorphism (PCR‐RFLP) analysis, we examined the point mutations of the XPA gene in 16 XPA patients, their parents, and their four asymptomatic siblings. We found that eight patients were homozygous for the AlwNI mutation, two were compound heterozygotes for the AIwNI mutation and the Hphl mutation, one was a compound heterozygote for the AIwNI mutation and the MseI mutation, three were compound heterozygotes for the AlwNl mutation and an unidentified mutation, and two were compound hcterozygotes for the Hphl mutation and an unidentified mutation, investigation of their clinical features suggested that the four patients who were heterozygous for the Hphl mutation and the AlwNI or an unidentified mutation had milder clinical manifestations such as later development of skin cancers and milder neurological deterioration, than those patients who were either homozygous for the AlwNI mutation or heterozygous for the AlwNI mutation and MseI mutation. PCR‐RFLP analysis of the XPA gene in the four asymptomatic siblings of the XPA patients revealed that two were carriers of the mutated XPA allele, one was not a carrier, and one was not diagnosed because of the presence of an unidentified mutation. These data indicate that determination of the point mutation of the XPAC gene is important in predicting the clinical course in XPA patients. In addition, this method is useful for the detection of asymptomatic carriers in affected families, who have not been identified with conventional techniques.
Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction.
Authors: H Ito, T Tomooka, N Sakai, H Yu, Y Higashino, K Fujii, T Masuyama, A Kitabatake, T Minamino
Journal: Circulation (1992)

We investigated myocardial perfusion dynamics after thrombolysis and its clinical implications.We studied 39 patients with acute anterior myocardial infarction (AMI). Myocardial contrast echocardiography (MCE) was performed before and immediately after successful reflow with intracoronary injection of sonicated Ioxaglate. The average segmental score by two-dimensional echocardiography (graded 0, normal, to 3, akinetic/dyskinetic) and global ejection fraction (left ventricular ejection fraction, LVEF%) by left ventriculography were measured at 1 day and at 4 weeks after reflow. Hypokinesis in the infarct region was assessed by the centerline method and expressed in terms of standard deviations (regional wall motion [RWM]: SD/chord) of normal. Immediately after reflow, 30 of 39 patients (group A) showed significant contrast enhancement within the risk area. The other nine patients (23%, group B), however, showed the residual contrast defect in the risk area (myocardial no reflow). There were no significant differences in the elapsed time, angiographic collateral grade, and degree of residual stenosis between group A and group B. Before reflow, both groups exhibited similar levels of global and regional left ventricular function. Improvement in global (LVEF, average segmental score) and regional left ventricular function was greater in group A than in group B (average segmental score, 0.44 +/- 0.41 versus 0.97 +/- 0.36, p less than 0.01; LVEF, 56.4 +/- 13.4 versus 42.7 +/- 8.9, p less than 0.05; RWM, -1.87 +/- 0.85 versus -3.18 +/- 0.52, p less than 0.005).MCE demonstrates that angiographically successful reflow cannot be used as an indicator of successful myocardial reperfusion in AMI patients. The residual contrast defect in the risk area demonstrated immediately after reflow is a predictor of poor functional recovery of the postischemic myocardium.
Nuclear Angiocardiography: Automated Selection of Regions of Interest for the Generation of Time-Activity Curves and Parametric Image Display and Interpretation
Authors: MICHAEL L. GORIS, DAVID BAUM, JOANNE WALLINGTON, JOSEPH P. KRISS
Journal: Clinical Nuclear Medicine (1976)

An automated method is presented in which regions of interest are selected on the basis of peak concentration times and in which the effects of overlap of left and right sided chambers or vessels are minimized by the automatic elimination of regions which have two distinct peak concentration times, one preceding the pulmonary phase of the study, and the other one following it. As part of the permanent record a set of parametric images is produced in which the progression of the bolus is represented in a pseudo gray scale with later times represented by darker shades. One of the parametric images documents the choice of the regions of interest, from each of which a time-activity curve is automatically generated. Besides providing the basis for these curves, the parametric images often help to clarify the nature of complex cardiac anomalies. Additional significant advantages of the method are minimal operator interaction and bias, and speed of analysis and presentation.
Brachial Plexus Radiculopathy and Computed Tomography
Authors: STANLEY R. PILLEMER
Journal: Annals of Internal Medicine (1984)

Letters and Corrections1 April 1984Brachial Plexus Radiculopathy and Computed TomographySTANLEY R. PILLEMER, M.D., PETER ASHBY, M.D., DUNCAN A. GORDON, M.D., KAREL G. TER BRUGGE, M.D.STANLEY R. PILLEMER, M.D.Search for more papers by this author, PETER ASHBY, M.D.Search for more papers by this author, DUNCAN A. GORDON, M.D.Search for more papers by this author, KAREL G. TER BRUGGE, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-100-4-619_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Computed tomography of the body is used frequently to diagnose lumbosacral disorders (1, 2). Compared to myelography, computed tomography has few adverse effects (3). We report the case of a patient with ankylosing spondylitis and the cauda equina syndrome (3, 4) who developed a severe brachial plexus palsy after a computed tomographic scan.A 65-year-old man developed low back pain at age 18. At age 32, ankylosing spondylitis was diagnosed and radiotherapy administered. By age 39 his spinal movement was very restricted. At age 58 he had weakness and numbness of the left leg. There were no...References1. ROSENTHALMANKINBAUMAN DHR. Musculoskeletal applications for computer tomography. Bull Rheum Dis. 1983;33:1-4. MedlineGoogle Scholar2. WITTENBERG J. Computer tomography of the body. N Engl J Med. 1983;309:1224-9. CrossrefMedlineGoogle Scholar3. KRAMERKROUTH LG. Computerized tomography, an adjunct to early diagnosis in the cauda equina syndrome of ankylosing spondylitis. Arch Neurol. 1978;35:116-8. CrossrefMedlineGoogle Scholar4. RUSSELLGORDONOGRYZLOMCPHEDRAN MDMR. The cauda equina syndrome of ankylosing spondylitis. Ann Intern Med. 1973;78:551-4. LinkGoogle Scholar5. MATTHEWS W. The neurological complications of ankylosing spondylitis. J Neurol Sci. 1968;6:561-73. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: STANLEY R. PILLEMER, M.D.; PETER ASHBY, M.D.; DUNCAN A. GORDON, M.D.; KAREL G. TER BRUGGE, M.D.Affiliations: Toronto Western Hospital Toronto, Ontario, M5T 2S8 Canada PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byConcise Communications 1 April 1984Volume 100, Issue 4Page: 619-619KeywordsAnkylosing spondylitisComputed axial tomographyLower back painParalysis ePublished: 1 December 2008 Issue Published: 1 April 1984 PDF downloadLoading ...
Diphosphonate Treatment of Calcinosis Universalis
Authors: Richard L. Cram, Riad Barmada, W. Blair Geho, Robert D. Ray
Journal: New England Journal of Medicine (1971)

CALCINOSIS universalis is a condition characterized by progressive accumulation of amorphous calcium phosphate and crystalline hydroxyapatite in subcutaneous lesions. The etiology is not known. Numerous modes of therapy have been proposed, including increased dietary phosphate, a diet low in calcium and high in phosphorus, a ketogenic diet, infusions of trisodium edetate (sodium versenate) to chelate calcium and systemic steroids. Surgical excision of the lesions followed by split-thickness skin grafting has also been recommended to eliminate painful infected lesions, but no method has been found that will consistently arrest or alleviate the disease.1 2 3 Fleisch has suggested that pyrophosphate may be a . . .
Pulmonary Resistance in Acquired Heart Disease
Authors: BERNARD L. CHARMS, BERNARD L. BROFMAN, PAUL M. KOHN
Journal: Circulation (1959)

Disproportionately high pulmonary artery pressures and pulmonary vascular resistance in acquired heart disease, particularly mitral stenosis, have been repeatedly observed. Seventeen patients with pulmonary hypertension secondary to elevated left atrial pressure have been studied by the method of temporary unilateral pulmonary artery occlusion: Resistances calculated before and after occlusion showed no change in most cases. The data show that despite very high initial resistance, increase in flow in the lung can occur with rapid reduction in resistance. It is suggested that "tone" of the pulmonary vasculature is operative even at very high pressure levels.
Follow up study of children born to mothers resident in Seascale, West Cumbria (birth cohort).
Authors: M J Gardner, A J Hall, S Downes, J D Terrell
Journal: BMJ (1987)

Records on 1068 children who were born to mothers resident in Seascale Civil Parish during 1950-83 were studied. There was a large degree of mobility among the families, and nearly half of the children did not subsequently attend the main local school. Use of the National Health Service Central Register, however, enabled us to follow up the children9s records regardless of place of residence. The excess of leukaemia among Seascale children first supported from the analysis of geographical areas is confirmed. There were five deaths from leukaemia identified to 30 June 1986 compared with 0.53 expected at national rates--a ratio of 9.36 (95% confidence interval 3.04 to 21.84). One of these deaths occurred after the child had left Seascale. There were four deaths from other cancers compared with 1.06 expected--a ratio of 3.76 (95% CI 1.02 to 9.63). In addition, three further cases of cancer, apart from the deaths, were reported compared with 1.19 expected since 1971--a ratio of 2.53 (95% CI 0.52 to 7.40). For other causes of death, including stillbirths and infant mortality, there was a reported deficit compared with national rates, some of which at least was to be expected on the basis of the social class composition of the population of Seascale. In view of the importance of this cohort of births continued follow up is planned, with the possibility of extending it to include births since 1983, and the methods available for this type of study will be examined further.
High Plasma Heparin Cofactor II Activity Is Associated With Reduced Incidence of In-Stent Restenosis After Percutaneous Coronary Intervention
Authors: Nobuyuki Takamori, Hiroyuki Azuma, Midori Kato, Shunji Hashizume, Ken-ichi Aihara, Masashi Akaike, Katsuya Tamura, Toshio Matsumoto
Journal: Circulation (2004)

Thrombin plays an important role in the development of atherosclerosis and restenosis after percutaneous coronary intervention. Because heparin cofactor II (HCII) inhibits thrombin action in the presence of dermatan sulfate, which is abundantly present in arterial wall, HCII may affect vascular remodeling by modulating thrombin action. We hypothesized that patients with high plasma HCII activity may show a reduced incidence of in-stent restenosis (ISR).Sequential coronary arteries (n=166) with NIR stent (Boston Scientific Corp) implantation in 134 patients were evaluated before, immediately after, and at 6 months after percutaneous coronary intervention. Patients were divided into the following groups: high HCII (> or =110%, 45 lesions in 36 patients), normal HCII (> or =80% and <110%, 81 lesions in 66 patients), and low HCII (<80%, 40 lesions in 32 patients). Percent diameter stenosis at follow-up in the high-HCII group (18.7%) was significantly lower (P=0.046) than that in the normal-HCII group (30.3%) or the low-HCII group (29.0%). The ISR rate in the high-HCII group (6.7%) was significantly lower than that in the low-HCII group (30.0%) (P=0.0039). Furthermore, multivariate analysis demonstrated that high plasma HCII activity is an independent factor in reducing the incidence of angiographic restenosis (odds ratio, 0.953/1% increase of HCII; 95% CI, 0.911 to 0.998).The results demonstrate that HCII may have a hitherto unrecognized effect in inhibiting ISR. The effect of HCII may be mediated by inactivating thrombin in injured arteries, thereby inhibiting vascular smooth muscle cell migration and proliferation.
Ultrasonic Blood Flow Measurement in Haemodialysis
Authors: D. Sampson, M. Papadimitriou, A. E. Kulatilake
Journal: BMJ (1970)

A 5-megacycle Doppler flow meter, calibrated in-vitro, was found to give a linear response to blood flow in the ranges commonly encountered in haemodialysis. With this, blood flow through artificial kidneys could be measured simply and with a clinically acceptable error. The method is safe, as blood lines do not have to be punctured or disconnected and hence there is no risk of introducing infection. Besides its value as a research tool the flow meter is useful in evaluating new artificial kidneys. Suitably modified it could form the basis of an arterial flow alarm system.
965. Antioxidant Enzyme Protection from HIV-1 gp120-Induced Neuronal Apoptosis by Gene Delivery Using rSV40 Vectors: Implication for Gene Therapy of AIDS
Authors: Lokesh Agrawal, David S. Strayer
Journal: Molecular Therapy (2005)

Human immunodeficiency virus-1 (HIV-1) infection causes neuronal toxicity and oxidative injury: HIV-1 gene products, especially gp120, induce free radical-mediated apoptosis. Nitric oxide (NO), when present in high concentrations, is a potential mediator of neuronal injury via upregulation of inducible nitric oxide synthase (iNOS) and formation of reactive oxygen species (ROS).We thus tested whether rSV40 gene delivery to central nervous system (CNS) can be exploited to protect the brain and mitigate HIV encephalopathy. We hypothesized that neurons, which readily form ROS as a result of HIV-1/gp120 exposure, could be protected using rSV40 viruses encoding Cu/Zn-superoxide dismutase (SOD1) and/or glutathione peroxidase (GPX1). Both of these enzymes detoxify oxygen free radical species. Our test system was cultured mature neurons derived from NT-2 cells. These were transduced with rSV40 vectors carrying SOD1 or GPX1, or control rSV40 vectors, and challenged by adding HIV-1 gp120. Apoptosis was measured by TUNEL assay. Transduction with SV(SOD1) and SV(GPX1) provided excellent transgene expression when tested in terminally differentiated NT-2 neurons, as assessed by western blotting, kinetic assays of enzyme activity and immunostaining. Transduction efficiency by the recombinant SV40 delivered vectors exceeded 95% as assayed by immunostaining. When used on NT2 derived neurons, gp120, induced apoptosis with a linear dose response relationship with an optimal concentration of 100 ng/ml (0.9 nm) for induction of apoptosis. SV(SOD1) and SV(GPX1) transduced cells, when challenged with this dose of gp120, were protected up to >90% from apoptosis, as tested using TUNEL assay. Protection was dose dependent: suboptimal transducing doses of these vectors protected less well. Combination transduction with both viruses (SOD1 and GPX1), showed >95% protection against gp120 apoptosis. We therefore demonstrate the effectiveness of SOD1 and GPX1 delivered by SV40 vectors, either singly or in combination, to protect neuronal cells susceptible to HIV-1. These findings may help to address issues related to gene delivery to the central nervous system and gene therapy to protect from the encephalopathy that attends HIV-1 infection in brain.